CNTA

Centessa Pharmaceuticals
CNTA
Market cap $1.65B

12.38 USD

+0.34

2.82%

At close Jun 13, 4:00 PM EDT

1 day

2.82%

5 days

2.82%

1 month

-0.64%

3 months

-26.62%

6 months

-25.29%

Year to date

-29.26%

1 year

24.67%

5 years

-43.08%

10 years

-43.08%

About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

Employees: 86

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

107% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 15

17% more funds holding in top 10

Funds holding in top 10: 12 [Q4 2024] → 14 (+2) [Q1 2025]

13% more funds holding

Funds holding: 114 [Q4 2024] → 129 (+15) [Q1 2025]

11% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 38

0.57% less ownership

Funds ownership: 94.36% [Q4 2024] → 93.79% (-0.57%) [Q1 2025]

14% less capital invested

Capital invested by funds: $2.08B [Q4 2024] → $1.8B (-$286M) [Q1 2025]

80% less call options, than puts

Call options by funds: $2.37M | Put options by funds: $11.7M

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$28

126%

upside

Avg. target

$33

165%

upside

High target

$38

207%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Needham Ami Fadia	183%upside $35	Buy Initiated	28 May 2025
Chardan Capital Rudy Li	142%upside $30	Buy Initiated	8 May 2025
Piper Sandler Biren Amin	207%upside $38	Overweight Initiated	31 Mar 2025
Guggenheim Debjit Chattopadhyay	126%upside $28	Buy Reiterated	26 Mar 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet

The consensus price target hints at a 138.8% upside potential for Centessa Pharmaceuticals (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

BOSTON and LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the first quarter ended March 31, 2025.

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2024.

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1) in participants with NT1, NT2 and IH.

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Centessa: Shift In Focus With ORX750 Development Continues To Pay Off

Centessa Pharmaceuticals shelved its SerpinPC candidate, which was being used to treat patients with Hemophilia B; Established net savings of $200 million because of this move. Positive interim and final analysis obtained from phase 1 study, using ORX750 for acutely sleep-deprived healthy volunteers; Positive outcome in terms of MWT and KSS efficacy measures. Results from several cohorts of phase 2a study using ORX750 to treat patients with NT1, NT2 and IH expected in 2025.

Centessa: Shift In Focus With ORX750 Development Continues To Pay Off

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

BOSTON and LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Wake Up to This Biotech Stock That Still Has Big Potential Upside

Centessa Pharmaceuticals NASDAQ: CNTA is a biotechnology stock that has nearly doubled its value so far this year, and its run may not be over. Analysts at Morgan Stanley have just massively raised their price target for the company.

Wake Up to This Biotech Stock That Still Has Big Potential Upside

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

See News Rankings

Charts implemented using Lightweight Charts™